Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Free Cash Flow (2021 - 2025)

Aligos Therapeutics' Free Cash Flow history spans 5 years, with the latest figure at -$21.7 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 18.16% year-over-year to -$21.7 million; the TTM value through Dec 2025 reached -$82.5 million, down 2.18%, while the annual FY2025 figure was -$82.5 million, 2.02% down from the prior year.
  • Free Cash Flow reached -$21.7 million in Q4 2025 per ALGS's latest filing, up from -$24.3 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$13.6 million in Q2 2023 to a low of -$37.8 million in Q4 2021.
  • Average Free Cash Flow over 5 years is -$22.0 million, with a median of -$21.3 million recorded in 2022.
  • Peak YoY movement for Free Cash Flow: surged 55.38% in 2022, then tumbled 43.16% in 2024.
  • A 5-year view of Free Cash Flow shows it stood at -$37.8 million in 2021, then surged by 55.38% to -$16.9 million in 2022, then crashed by 34.28% to -$22.7 million in 2023, then grew by 18.78% to -$18.4 million in 2024, then fell by 18.16% to -$21.7 million in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Free Cash Flow are -$21.7 million (Q4 2025), -$24.3 million (Q3 2025), and -$15.5 million (Q2 2025).